Can you describe kymriah's persistence in the body over time?

Short answer: after Kymriah (tisagenlecleucel) is given, the engineered T cells expand in the body within the first week or two, and then can persist for months to years in some patients. The duration of persistence varies a lot between people and between diseases.

What the typical time course looks like
- Expansion (early phase): CAR-T cells usually proliferate in the first 1–2 weeks after infusion, often peaking around day 7–14. The size of this expansion is related to how well the therapy works.
- Peak and early persistence: after the peak, cells remain in the blood and bone marrow for weeks to months.
- Long-term persistence: in many patients, CAR-T cells continue to be detectable for months and, in some cases, years. Long-term persistence is more commonly observed in pediatric/young adult ALL but can occur in others as well.
- Pharmacodynamic marker: B-cell aplasia (absence of normal B cells) often tracks with ongoing CAR-T activity. If CAR-T cells decline, B cells may start to recover, which can indicate waning CAR-T persistence.

What influences how long persistence lasts
- Disease type and burden: pediatric/young adult ALL tends to show stronger and longer persistence than some adult lymphomas.
- CAR design: tisagenlecleucel uses a 4-1BB co-stimulatory domain, which is generally associated with longer persistence than some other CAR constructs.
- Lymphodepletion: the conditioning regimen before CAR-T infusion (often fludarabine/cyclophosphamide) helps the CAR-T cells expand and persist.
- T-cell quality and composition: the ratio of CD4+ to CD8+ T cells and the presence of memory T cells can affect persistence.
- Prior therapies and patient factors: heavily pretreated patients or those with certain immune profiles may have different persistence patterns.

Clinical implications and monitoring
- Longer persistence can mean more durable responses, but also longer duration of B-cell aplasia and possible hypogammaglobulinemia, which may require IVIG and infection precautions.
- Relapse after CAR-T can occur if CAR-T cells are no longer present (loss of persistence) or if the cancer cells lose the CD19 target (antigen loss).
- CAR-T persistence is typically monitored by detecting the CAR transgene in blood (via PCR) or by identifying CAR-expressing T cells (flow cytometry).

If you’d like, I can summarize specific persistence data from the FDA label or key clinical studies for Kymriah, or tailor the explanation to a particular patient scenario (e.g., pediatric ALL vs adult DLBCL).